Tesamorelin: what the research actually says

Most peptide pages on this site are about compounds with promising animal data and an evidence gap where human trials should be. Tesamorelin is the exception, and it's useful precisely because of that contrast: it shows what it actually takes for a peptide to clear the FDA's bar, and how narrow an "approved" label can be even when it's real.

What tesamorelin is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), made by Theratechnologies and sold under the brand names Egrifta and, since a 2019 reformulation, Egrifta SV. Unlike synthetic human growth hormone (HGH) injections, tesamorelin does not supply growth hormone directly. Instead, it works upstream: it binds to GHRH receptors in the pituitary gland and prompts the pituitary to release the body's own endogenous GH in a pulsatile, physiological pattern — the way healthy growth hormone secretion normally works.

That mechanism matters for two reasons. First, pulsatile GH release is thought to carry a somewhat more favorable safety profile than continuous exogenous GH. Second, the pituitary's response is self-limiting in ways that direct HGH injection is not: the body retains some feedback control via somatostatin, the hormone that normally shuts off GH production. Even so, tesamorelin still elevates IGF-1 substantially, which is why the FDA requires monitoring — see the safety section below.

FDA approval: what it actually covers

The FDA approved tesamorelin (BLA 022505) in November 2010.¹ Its approved indication is narrow and specific: "reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy." The label is explicit about the limits of that approval: "EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect."⁴ That single sentence separates tesamorelin from most peptides marketed for general fat loss: the FDA-reviewed data specifically found it does not work that way overall, even though it reduces a particular type of fat in a particular patient population.

What the efficacy evidence shows

A 2026 meta-analysis pooling five randomized controlled trials of tesamorelin in HIV-associated lipodystrophy found statistically significant reductions in visceral adipose tissue (mean difference −27.71 cm²), trunk fat (−1.18 kg), and hepatic fat percentage (−4.28%), plus a significant increase in lean body mass (+1.42 kg) — all with P values below 0.001.² Consistent with the FDA label, the same analysis found no significant change in overall BMI, confirming its "weight neutral" characterization. Reported adverse events included arthralgia, muscle pain, tingling sensations, and injection-site reactions, without significant disruption to blood glucose.²

"Insulin and GLP-1s are designed for specific disease, so we know who's a good candidate for them."

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, discussing what separates well-studied, approved peptide drugs from newer, unapproved ones, in the American Medical Association (April 2026). Tesamorelin follows the same pattern: a defined patient population, defined trials, and FDA-reviewed prescribing guidance.

The liver fat finding: a secondary but significant result

A separate line of tesamorelin research has investigated its effect on non-alcoholic fatty liver disease (NAFLD) in people with HIV — a population with unusually high rates of hepatic steatosis due to antiretroviral therapy and HIV-related metabolic changes. A randomized, double-blind, multi-center trial published in The Lancet HIV and funded by the National Institutes of Health enrolled 61 participants with HIV and a hepatic fat fraction of 5 percent or more, and randomized them to tesamorelin or placebo for 12 months.⁵

The result was meaningful: patients receiving tesamorelin had an absolute reduction in hepatic fat fraction of −4.1 percentage points compared to placebo (95% CI −7.6 to −0.7; p=0.018), corresponding to a relative reduction of 37 percent from baseline. More striking was the resolution rate: 35 percent of patients receiving tesamorelin achieved a hepatic fat fraction below 5 percent — the threshold for normal — versus only 4 percent of those on placebo (p=0.0069). Changes in fasting glucose and glycated hemoglobin were not significantly different between groups at 12 months.⁵

This research is not part of tesamorelin's approved indication, and the trial authors themselves noted further study is needed on long-term liver histology outcomes. But it represents one of the very few pharmacological interventions to show this effect in HIV-NAFLD in a rigorous trial.

Evidence grade table

The following summarizes what the clinical evidence actually supports, graded by study quality. "Moderate" reflects consistent RCT data with some limitations; "Low–Moderate" reflects a single trial or shorter follow-up.

What "approved" looks like, concretely

Safety and required monitoring

Because tesamorelin increases growth hormone and therefore IGF-1, the FDA requires active monitoring during treatment. The prescribing information reports that among patients who received Egrifta for 26 weeks, 47 percent had IGF-1 levels greater than 2 standard deviations above normal, and 36 percent had levels more than 3 standard deviations above normal — with this effect observable as early as 13 weeks of treatment.⁴ For patients who continued to week 52, those numbers declined somewhat (34 percent above 2 SDS; 23 percent above 3 SDS), but the elevation remained substantial.

The clinical consequences matter. IGF-1 is a known growth factor, and tesamorelin is contraindicated in patients with active malignancy and requires careful evaluation in patients with a history of cancer. Separately, the FDA label flags glucose risk: the rate of patients developing HbA1c levels at or above 6.5 percent (the diabetes threshold) was 5 percent in the Egrifta group versus 1 percent in placebo, yielding a hazard odds ratio of 3.3 (95% confidence interval 1.4 to 9.6).⁴ That's a more than threefold elevated diabetes risk during trials — a meaningful signal in a drug often discussed in wellness contexts without this context.

Additional adverse effects from clinical trial data include injection site reactions in 25 percent of treated patients (versus 14 percent on placebo), hypersensitivity reactions in 4 percent, and fluid retention effects including arthralgia, carpal tunnel syndrome, and edema.⁴

What happens when treatment is discontinued

Tesamorelin's effects on visceral fat are not permanent. When patients discontinue treatment, visceral adipose tissue returns toward baseline, typically within months. This is not a flaw in how the drug was designed — it reflects the underlying biology: growth hormone affects fat metabolism continuously, and when the signal is removed, the metabolic effect reverses. Clinical trial data showed that visceral fat reductions observed during the treatment period did not persist in patients who stopped.

For the patient population tesamorelin was designed for — people with HIV-associated lipodystrophy managing a chronic condition — this means ongoing treatment and ongoing monitoring. The long-term cardiovascular safety of sustained use has not been established; the FDA label explicitly flags this limitation. For people considering tesamorelin for general wellness or aesthetic reasons, the discontinuation reversal is a practical consideration on top of the off-label status: any effect would require continuous use and continuous monitoring.

The off-label risk worth knowing

Because tesamorelin raises growth hormone, it's sometimes sought outside its approved use, for general fat loss, muscle gain, or anti-aging, by people who don't have HIV-associated lipodystrophy. That use falls outside the population the trials studied and outside what the FDA reviewed. An approved drug used off-label, without the diagnosis and monitoring it was studied for, loses much of the safety margin that made it approvable in the first place. The monitoring requirements in the label — IGF-1 levels, glucose, assessment of malignancy risk — exist because tesamorelin's mechanism generates real biological risk that requires active clinical oversight.

For context on how peptides in general compare to approved drugs in terms of evidence and access, and what the FDA's regulatory framework actually covers, see our overview on peptide legality and the broader safety picture across the peptide category.